ArticleCombinatorial chemistry & high throughput screening2026
Sanggenol L Activates Caspase and Inhibits the NF-κ B/JNK/ERK Signaling Pathway to Promote Apoptotic Cell Death in Colorectal Cancer Cells.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Valorization of Sardinian Grapevine Leaves as a Sustainable Source of Flavonols with Anticancer Potential.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn Western nations, colorectal cancer is the most prevalent type of cancer. Recent research has revealed that Western habits are influencing Asian countries, thus significantly contributing to the rapidly increasing rate of cancer. A naturally occurring flavonoid called sanggenol L found in the root bark of Morus alba possesses anti-cancer properties against colorectal malignant cells. The cellular and molecular mechanisms underlying the effects of sanggenol L on human colorectal cancer cells are still unknown.
objectiveThe current study explored whether sanggenol L enhances apoptosis through the inhibition of the NF-κB/JNK/ERK signaling pathway in colorectal human cancer cells. MATERIALS AND
methodsThe anti-colon cancer effect of sanggenol L were determined based on the observed cytotoxic activity, fluorescent staining for apoptotic cells using AO/EB, DCFHDA, Rh-123, DAPI, ROS, and MMP, as well as the analysis of cell proliferation, inflammatory and apoptotic markers through western blot analysis.
resultsColorectal cancer cells exposed to sanggenol L (20 and 30 μM/ml) mediated apoptosis of Bax, Bcl-2, and TNF-α and reduced cell growth by down-regulating p-ERK, p-JNK, and pp38 via mediation of p-NF-κB.
conclusionThe study results indicate that sanggenol L triggers caspase-induced apoptosis in colorectal cancer cells. Lastly, it was proposed that sanggenol L could help prevent colon cancer.
Indexed as
Identifiers
40183278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.